Literature DB >> 17065337

Splanchnic cortisol production in dogs occurs primarily in the liver: evidence for substantial hepatic specific 11beta hydroxysteroid dehydrogenase type 1 activity.

Rita Basu1, Dale S Edgerton, Ravinder J Singh, Alan Cherrington, Robert A Rizza.   

Abstract

Eight dogs underwent combined hepatic/portal vein catheterization and infusion of D4-cortisol in order to determine the relative contributions of the viscera and liver to splanchnic cortisol production. D4-cortisol concentrations progressively decreased from 2.6 +/- 0.1 to 2.4 +/- 0.1 to 1.7 +/- 0.1 microg/dl (P < 0.001 by ANOVA) from hepatic artery to portal vein to hepatic vein, respectively, indicating 8 +/- 3 and 28 +/- 3% extraction across the viscera and liver, respectively. On the other hand, hepatic artery, portal vein, and hepatic vein cortisol concentrations did not differ (0.31 +/- 0.12 vs. 0.28 +/- 0.11 vs. 0.27 +/- 0.10 microg/dl, respectively), indicating zero net cortisol balance. This meant that 1.0 +/- 0.1 microg/min of cortisol was produced within the splanchnic bed, all of which occurred within the liver (1.2 +/- 0.1 microg/min). On the other hand, visceral cortisol production did not differ from zero (-0.2 +/- 0.2 microg/min; P < 0.001 vs. liver). Flux through the 11beta hydroxysteroid dehydrogenase (HSD) type 1 pathway can be measured by determining the rate of conversion of D4-cortisol to D3-cortisol. D3-cortisol concentrations were lower in the portal vein than hepatic artery (0.45 +/- 0.03 vs. 0.48 +/- 0.02, respectively; P < 0.01) but did not differ in the portal vein and hepatic vein, indicating net uptake across the viscera but zero balance across the liver. D3-cortisol production with the viscera and liver averaged 0.2 +/- 0.1 microg/min (P = NS vs. zero production) and 0.6 +/- 0.1 microg/min (P < 0.001 vs. zero production; P < 0.001 vs. viscera production), respectively. We conclude that most, if not all, of splanchnic cortisol production occurs within the liver. Taken together, these data suggest that the high local cortisol concentrations generated via the 11beta HSD type 1 pathway within the liver likely contribute to the regulation of hepatic glucose, fat, and protein metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065337     DOI: 10.2337/db06-0601

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Rita Basu; Christopher J Ramnanan; Tiffany D Farmer; Doss Neal; Melanie Scott; Peer Jacobson; Robert A Rizza; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-02-16       Impact factor: 4.310

2.  Translating PUFA omega 6:3 ratios from wild to captive hibernators (Urocitellus parryii) enhances sex-dependent mass-gain without increasing physiological stress indicators.

Authors:  Monica Mikes; Sarah A Rice; Doug Bibus; Alexander Kitaysky; Kelly L Drew
Journal:  J Comp Physiol B       Date:  2022-05-03       Impact factor: 2.230

3.  Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Authors:  Rita Basu; Ananda Basu; Meagan Grudzien; Paul Jung; Peer Jacobson; Michael Johnson; Ravinder Singh; Michael Sarr; Robert A Rizza
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

4.  Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Authors:  Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

5.  Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis.

Authors:  J J Winnick; C J Ramnanan; V Saraswathi; J Roop; M Scott; P Jacobson; P Jung; R Basu; A D Cherrington; D S Edgerton
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

6.  Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats.

Authors:  Esben S Buhl; Thomas Korgaard Jensen; Niels Jessen; Betina Elfving; Christian S Buhl; Steen B Kristiansen; Rasmus Pold; Lasse Solskov; Ole Schmitz; Gregers Wegener; Sten Lund; Kitt Falck Petersen
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

Review 7.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

8.  Diet-induced weight loss has chronic tissue-specific effects on glucocorticoid metabolism in overweight postmenopausal women.

Authors:  A Stomby; K Simonyte; C Mellberg; M Ryberg; R H Stimson; C Larsson; B Lindahl; R Andrew; B R Walker; T Olsson
Journal:  Int J Obes (Lond)       Date:  2014-10-28       Impact factor: 5.095

9.  Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.

Authors:  Yogesh Yadav; Kelly Dunagan; Rachita Khot; Sudhakar K Venkatesh; John Port; Alfonso Galderisi; Claudio Cobelli; Craig Wegner; Ananda Basu; Rickey Carter; Rita Basu
Journal:  Diabetes Obes Metab       Date:  2022-01-25       Impact factor: 6.408

10.  Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

Authors:  Paul M Stewart; Jeremy W Tomlinson
Journal:  Diabetes       Date:  2009-01       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.